Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Keppra

- PMLiVE

AbbVie announces FDA approval of antibiotic combination for intra-abdominal infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

FDA approves Supernus Pharmaceuticals’ Onapgo to treat advanced Parkinson’s disease

The neurodegenerative disorder affects almost one million people in the US

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

Biogen Idec building

Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

The neuromuscular disease affects approximately one in every 10,000 babies worldwide

- PMLiVE

Novo Nordisk’s Ozempic granted FDA approval in chronic kidney disease

The progressive condition affects approximately 40% of type 2 diabetes patients

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

Biogen Idec building

Biogen/Eisai’s Alzheimer’s drug approved by FDA for monthly maintenance dosing

The neurodegenerative disease affects almost seven million people in the US

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Datroway granted FDA approval in breast cancer

More than 300,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

- PMLiVE

FDA accepts updated protocol for Annovis’ phase 3 Alzheimer’s disease study

The company hopes the revised protocol will accelerate the development timeline of buntanetap

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links